Zohra Nooruddin MD | UT Health San Antonio MD Anderson Cancer Center

About Me

About Zohra Nooruddin, MD

Zohra Nooruddin, MD, is an associate professor in the Division of Hematology-Oncology at The University of Texas Health Science Center San Antonio. She is a hematologist specializing in adult blood cancers and disorders at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center.

She received her medical degree from Ziauddin University Medical College in Karachi, Pakistan, and attended Mount Sinai School of Medicine in Englewood, New Jersey, for her residency. Dr. Nooruddin completed a symptom control and palliative care fellowship at MD Anderson Cancer Center in Houston and an additional fellowship in hematology-oncology at the University of Colorado Denver. She is board-certified in hospice and palliative medicine and hematology and oncology.

Gender

Female

Languages Spoken

Hindi
Urdu

Credentials

Positions

Associate Professor, Division of Hematology-Oncology, University of Texas Health Science Center San Antonio
Associate Director, Bone Marrow Transplant, UT Health San Antonio MD Anderson Cancer Center

Certifications

American Board of Internal Medicine (Hospice and Palliative Medicine)
American Board of Internal Medicine (Hematology)
American Board of Internal Medicine (Medical Oncology)

Education

Medical School: Ziauddin University Medical College, Karachi, Pakistan
Fellowship: Hospice and Palliative Care, The University of Texas MD Anderson Cancer Center, Houston, Texas
Fellowship: Hematology-Oncology, University of Colorado, Denver, Colorado
Residency: Internal Medicine, Mount Sinai School of Medicine, Englewood, New Jersey

Locations & Contact

Urschel Building

7979 Wurzbach Road
San Antonio, TX 78229

Make an appointment

29.513005979566, -98.580601215363

Research & Publications

Hyperviscosity Syndrome in Undifferentiated Connective Tissue Disease: A Diagnostic and Therapeutic Challenge

Clinical Characteristics, Treatment Patterns, and Outcomes of Patients With Locally Advanced/Metastatic Hepatocellular Carcinoma Treated at the Veterans Health Administration

The Impact of Time From Diagnosis to Initiation of Chemotherapy on Survival of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma in the Veterans Health Administration

View All Publications - Zohra Nooruddin

Clinical Trials

Type of Cancer

Leukemia, other, Chronic Myelogenous Leukemia (CML)

ClinicalTrials.gov Identifier

NCT05384587

Principal Investigator

Zohra Nooruddin MD

A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia

This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP-binding site TKI with discontinuation due to treatment failure, warning, or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.